Evidence map›Paper›PMID 27847991›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2017

Synthesis and pre-clinical evaluation of a new class of high-affinity

James Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, Dohyun Kim, Clarence Williams, Shashikanth Ponnala, John W Babich

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. TheEuropean journal of nuclear medicine and molecular imaging · 2017
    Trial
  3. The development ofEJNMMI radiopharmacy and chemistry · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Head-to-Head Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Otto: a 4.04 GBq (109 mCi)EJNMMI radiopharmacy and chemistry · 2020
    Article
  12. Article
  13. Review
  14. Initial evaluation of PET/CT withCancer science · 2019
    Article
  15. La Radiologia medica · 2018
    Review
  16. Article
  17. The use of PET/CT in prostate cancer.Prostate cancer and prostatic diseases · 2018
    Review
  18. Current status of theranostics in prostate cancer.European journal of nuclear medicine and molecular imaging · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

James KellyDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.
Alejandro Amor-CoarasaDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.
Anastasia NikolopoulouDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.
Dohyun KimCitigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, 10021, USA.
Clarence WilliamsDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.
Shashikanth PonnalaDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.
John W BabichDivision of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA. job2060@med.cornell.edu.
Cornell University · USWeill Cornell Medicine · USCitigroup · USMolecular Innovations (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCurrent clinical imaging of PSMA-positive prostate cancer by positron emission tomography (PET) mainly features

methodsSix triazolylphenyl ureas and their alkyne precursors were synthesized from the Glu-urea-Lys PSMA binding moiety. PSMA affinity was determined in a competitive binding assay using LNCaP cells. The [

resultsF-18-labeled triazolylphenyl ureas were prepared with a decay-corrected RCY of 20-40 %, >98 % radiochemical and chemical purity, and specific activity of up to 391 GBq/μmol. PSMA binding (IC

conclusionsSix [

Indexed as

Positron-Emission TomographyAnimalsAntigens, SurfaceCell Line, TumorFluorine RadioisotopesGlutamate Carboxypeptidase IIHumansLigandsMaleMiceMice, NudePhenylurea CompoundsProstatic NeoplasmsProtein BindingRadiopharmaceuticalsTissue DistributionAntigens, SurfaceFluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IILigandsPhenylurea CompoundsRadiopharmaceuticalsTriazolesFluorine-18Prostate cancerPSMATriazolylphenyl ureas

Identifiers

PMID27847991
PMCPMC5323493
OpenAlexW2551224209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.